Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies-Reference-Cited by-同舟云学术

Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies

Published:2024-08-15 Issue:17 Volume:67 Page:14702-14722
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhou Yang¹^ORCID,Kang Jibo¹,Lu Xiaoyun¹^ORCID

Affiliation:

1. State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education, Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, #855 Xingye Avenue, Guangzhou 510632, China

Funder

Changjiang Scholar Program, Ministry of Education

State Key Laboratory of Respiratory Disease

Basic and Applied Basic Research Foundation of Guangdong Province

Guangzhou Municipal Science and Technology Bureau

Fundamental Research Funds for the Central Universities

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00361

Reference120 articles.

1. Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2. Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations

3. Targeting Gatekeeper Mutations for Kinase Drug Discovery

4. Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant

5. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations